A simple protein-based SARS-CoV-2 surrogate neutralization assay

Kento T Abe; Zhijie Li; Reuben Samson; Payman Samavarchi-Tehrani; Emelissa J Valcourt; Heidi Wood; Patrick Budylowski; Alan P. Dupuis II; Roxie C Girardin; Bhavisha Rathod; Karen Colwill; Allison J. McGeer; Samira Mubareka; Jennifer L. Gommerman; Yves Durocher; Mario Ostrowski; Kathleen A McDonough; Michael A. Drebot; Steven J. Drews; James M Rini; Anne-Claude Gingras.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-197913

Documentos relacionados

  1. A simple protein-based surrogate neutralization assay for SARS-CoV-2.
  2. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
  3. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.
  4. Mechanisms of SARS-CoV-2 entry into cells.
  5. Myeloid dysregulation and therapeutic intervention in COVID-19.
  6. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
  7. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
  8. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
  9. Targeting SARS-CoV-2 by synthetic dual-acting thiol compounds that inhibit Spike/ACE2 interaction and viral protein production.
  10. Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay.